Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas

被引:52
作者
Prat, R. [1 ]
Galeano, I. [1 ]
Lucas, A. [2 ]
Martinez, J. C. [2 ]
Martin, M. [3 ]
Amador, R. [4 ]
Reynes, G. [3 ]
机构
[1] Hosp Univ La Fe Avda, Dept Neurosurg, Valencia 46009, Spain
[2] Hosp Univ La Fe, Dept Radiol, Valencia, Spain
[3] Hosp Univ La Fe, Dept Med Oncol, Valencia, Spain
[4] Hosp Univ La Fe, Dept Radiat Oncol, Valencia, Spain
关键词
Glioma; Perfusion; PET; Recurrence; Spectroscopy; H-1 MR SPECTROSCOPY; BRAIN-TUMORS; RADIATION NECROSIS; F-18; FLUORODEOXYGLUCOSE; STEREOTACTIC BIOPSY; PET; DIFFERENTIATION; RADIOTHERAPY; ASTROCYTOMA; PROGRESSION;
D O I
10.1016/j.jocn.2009.02.035
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In a consecutive series of 26 previously operated patients diagnosed with cerebral glioma, magnetic resonance spectroscopy (MRS), 2-(F-18) fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and perfusion MRI (MRP), were performed at follow-up to distinguish recurrence from radiation necrosis, and to identify tumour upgrading. Discrepancy between techniques was observed in 9 cases. The positive predictive value (PPV) and the negative predictive value (NPV) of each technique to detect the presence of high grade glioma was: MRI, PPV = 50%; MRS, PPV = 91.6%, NPV = 100%; FDG-PET, PPV = 75%, NPV = 61.1%: MRP, PPV = 100%, NPV = 100%. In the selected group of nine cases studied to differentiate viable turnout from radiation necrosis, MRS and MRP reached a PPV and a NPV of 100%, whereas for FDG-PET, PPV and NPV were 66.6% and 60%, respectively. To distinguish between viable high-grade glioma and radiation necrosis, gadolinium-enhanced MRI gives a high false-positive rate, while MRS and MRP are superior to FDG-PET in discriminating turnout recurrence, grade increase and radiation necrosis. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:50 / 53
页数:4
相关论文
共 24 条
[11]   The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours - A prospective study [J].
Kreth, FW ;
Muacevic, A ;
Medele, R ;
Bise, K ;
Meyer, T ;
Reulen, HJ .
ACTA NEUROCHIRURGICA, 2001, 143 (06) :539-545
[12]  
Law M, 2003, AM J NEURORADIOL, V24, P1989
[13]   Metabolic imaging to follow stereotactic radiation of gliomas -: the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT [J].
Lichy, MP ;
Henze, M ;
Plathow, C ;
Bachert, P ;
Kauczor, HU ;
Schlemmer, HP .
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2004, 176 (08) :1114-1121
[14]   Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy [J].
Lichy, MP ;
Bachert, P ;
Henze, M ;
Lichy, CM ;
Debus, J ;
Schlemmer, HP .
NEURORADIOLOGY, 2004, 46 (02) :126-129
[15]   Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence [J].
McKnight, TR ;
von dem Bussche, MH ;
Vigneron, DB ;
Lu, Y ;
Berger, MS ;
McDermott, MW ;
Dillon, WP ;
Graves, EE ;
Pirzkall, A ;
Nelson, SJ .
JOURNAL OF NEUROSURGERY, 2002, 97 (04) :794-802
[16]   The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment [J].
Mehrkens, J. H. ;
Poepperl, G. ;
Rachinger, W. ;
Herms, J. ;
Seelos, K. ;
Tatsch, K. ;
Tonn, J. C. ;
Kreth, F. W. .
JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (01) :27-35
[17]   Delayed development of radiation vasculopathy of the brain stem confirmed by F-18FDG PET in a case of anaplastic astrocytoma [J].
Muthukrishnan, Ashok ;
Bajoghli, Mehran ;
Mountz, James M. .
CLINICAL NUCLEAR MEDICINE, 2007, 32 (07) :527-531
[18]  
OGAWA T, 1991, ACTA RADIOL, V32, P197
[19]  
OSTERTAG CB, 1980, SURG NEUROL, V14, P275
[20]   Transient MRI enhancement in a patient with seizures and previously resected glioma: Use of MRS [J].
Quan, D ;
Hackney, DB ;
Pruitt, AA ;
Lenkinski, RE ;
Cecil, KM .
NEUROLOGY, 1999, 53 (01) :211-213